

# BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number  
**WO 2005/032586 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/12**, (74) Common Representative: **MERCK & CO., INC.?**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).  
C12N 15/37, 15/81, C07K 14/025

(21) International Application Number:  
PCT/US2004/031326

(22) International Filing Date:  
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/506,812 29 September 2003 (29.09.2003) US

(71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRYAN, Jaine, T.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **BROWNLOW, Michelle, K.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **SCHULTZ, Loren, D.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **JANSEN, Kathrin, U.** [DE/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OPTIMIZED EXPRESSION OF HPV 45 L1 IN YEAST

(57) Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.



WO 2005/032586 A1

## TITLE OF THE INVENTION

## OPTIMIZED EXPRESSION OF HPV 45 L1 IN YEAST

## FIELD OF THE INVENTION

5           The present invention relates generally to the therapy of human papillomavirus (HPV). More specifically, the present invention relates to synthetic polynucleotides encoding HPV45 L1 protein, and to recombinant vectors and hosts comprising said polynucleotides. This invention also relates to HPV45 virus-like particles (VLPs), wherein the VLPs are produced by expressing recombinant HPV 45 L1 or L1 + L2 in yeast cells and to their use in vaccines and pharmaceutical compositions for preventing  
10   and treating HPV.

## BACKGROUND OF THE INVENTION

          There are more than 80 types of human papillomavirus (HPV), many of which have been associated with a wide variety of biological phenotypes, from benign proliferative warts to malignant  
15   carcinomas (for review, *see* McMurray et al., *Int. J. Exp. Pathol.* 82(1): 15-33 (2001)). HPV6 and HPV11 are the types most commonly associated with benign warts and/or nonmalignant condyloma acuminata of the genital or respiratory mucosa. HPV16 and HPV18 are the high-risk types most frequently associated with *in situ* and invasive carcinomas of the cervix, vagina, vulva and anal canal. More than 90% of cervical carcinomas are associated with infections of HPV16, HPV18 or the less  
20   prevalent oncogenic types HPV31, -33, -45, -52 and -58 (Schiffman et al., *J. Natl. Cancer Inst.* 85(12): 958-64 (1993)). The observation that HPV DNA is detected in more than 90% of cervical cancers provides strong epidemiological evidence that HPVs cause cervical carcinoma (*see* Bosch et al., *J. Natl. Cancer Inst.* 87(11): 796-802 (1995)).

          Papillomaviruses are small (50-60 nm), nonenveloped, icosahedral DNA viruses that  
25   encode up to eight early and two late genes. The open reading frames (ORFs) of the viral genomes are designated E1 to E7, and L1 and L2, where "E" denotes early and "L" denotes late. L1 and L2 code for virus capsid proteins, while the E genes are associated with functions such as viral replication and cellular transformation.

          The L1 protein is the major capsid protein and has a molecular weight of 55-60 kDa.  
30   The L2 protein is the minor capsid protein. Immunological data suggest that most of the L2 protein is internal to the L1 protein in the viral capsid. Both the L1 and L2 proteins are highly conserved among different papillomaviruses.

          Expression of the L1 protein or a combination of the L1 and L2 proteins in yeast, insect cells, mammalian cells or bacteria leads to self-assembly of virus-like particles (VLPs) (for review, *see*  
35   Schiller and Roden, in *Papillomavirus Reviews: Current Research on Papillomaviruses*; Lacey, ed.

Leeds, UK: Leeds Medical Information, pp 101-12 (1996)). VLPs are morphologically similar to authentic virions and are capable of inducing high titres of neutralizing antibodies upon administration into an animal. Because VLPs do not contain the potentially oncogenic viral genome, they present a safe alternative to the use of live virus in HPV vaccine development (for review, *see* Schiller and Hidesheim, *J. Clin. Virol.* 19: 67-74 (2000)). For this reason, the L1 and L2 genes have been identified as immunological targets for the development of prophylactic and therapeutic vaccines for HPV infection and disease.

HPV vaccine development and commercialization have been hindered by difficulties associated with obtaining high expression levels of exogenous genes in successfully transformed host organisms, limiting the production of purified protein. Therefore, despite the identification of wild-type nucleotide sequences encoding HPV L1 proteins such as HPV45 L1 protein, it would be highly desirable to develop a readily renewable source of crude HPV L1 protein that utilizes HPV45 L1-encoding nucleotide sequences that are optimized for expression in the intended host cell. Additionally, it would be useful to produce large quantities of HPV45 L1 VLPs having the immunity-conferring properties of the native proteins for use in vaccine development.

## SUMMARY OF THE INVENTION

The present invention relates to compositions and methods to elicit or enhance immunity to the protein products expressed by HPV45 L1 genes, which have been associated with cervical cancer. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The present invention further provides HPV45 virus-like particles (VLPs), wherein said VLPs are produced by expressing recombinant HPV45 L1 or L1 + L2 in yeast cells and discloses use of HPV45 VLPs in pharmaceutical compositions and vaccines for the prevention and/or treatment of HPV-associated cancer.

The present invention relates to synthetic DNA molecules encoding the HPV45 L1 protein. The codons of the synthetic molecules are designed so as to use the codons preferred by a yeast cell. The synthetic molecules may be used as a source of HPV45 L1 protein, which may self-assemble into VLPs. Said VLPs may be used in a VLP-based vaccine.

An exemplary embodiment of the present invention comprises a synthetic nucleic acid molecule which encodes the HPV45 L1 protein as set forth in SEQ ID NO:2, said nucleic acid molecule comprising a sequence of nucleotides as set forth in SEQ ID NO:1.

Also provided are recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification.

The present invention also relates to a process for expressing an HPV45 L1 protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid encoding an

HPV45 L1 protein into a yeast host cell; and (b) culturing the yeast host cell under conditions which allow expression of said HPV45 L1 protein.

The present invention further relates to a process for expressing an HPV45 L1 protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid encoding an HPV45 L1 protein into a yeast host cell; wherein the nucleic acid molecule is codon-optimized for optimal expression in the yeast host cell and; (b) culturing the yeast host cell under conditions which allow expression of said HPV45 L1 protein.

In preferred embodiments, the nucleic acid comprises a sequence of nucleotides as set forth in SEQ ID NO:1 (45 L1 R sequence).

This invention also relates to HPV45 virus-like particles (VLPs) which are produced in yeast cells, methods of producing HPV45 VLPs, and methods of using HPV45 VLPs.

In a preferred embodiment of the invention, the yeast is selected from the group consisting of: *Saccharomyces cerevisiae*, *Hansenula polymorpha*, *Pichia pastoris*, *Kluyveromyces fragilis*, *Kluyveromyces lactis*, and *Schizosaccharomyces pombe*.

Another aspect of this invention is an HPV45 VLP, wherein the VLP is produced by recombinant expression of HPV45 L1 or HPV45 L1 + L2 in a yeast cell.

Yet another aspect of this invention is an HPV45 VLP which comprises an HPV45 L1 protein encoded by a codon-optimized HPV45 L1 gene. In an exemplary embodiment of this aspect of the invention, the codon-optimized HPV45 L1 gene comprises a sequence of nucleotides as set forth in SEQ ID NO:1.

This invention also provides a method for inducing an immune response in an animal comprising administering HPV45 virus-like particles to the animal. In a preferred embodiment, the HPV45 VLPs are produced by a codon-optimized gene.

Yet another aspect of this invention is a method of preventing or treating HPV-associated cervical cancer comprising administering to a mammal a vaccine comprising HPV45 VLPs. In a preferred embodiment of this aspect of the invention, the HPV45 VLPs are produced in yeast.

This invention also relates to a vaccine comprising HPV45 virus-like particles (VLPs).

In an alternative embodiment of this aspect of the invention, the vaccine further comprises VLPs of at least one additional HPV type. The at least one additional HPV type may be any HPV type of interest, including any HPV type described in the art or those subsequently identified. In a preferred embodiment, the HPV type is a type that is associated with a clinical phenotype such as warts or cervical cancer. In a further preferred embodiment, the at least one additional HPV type is selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, and HPV68.

This invention also relates to pharmaceutical compositions comprising HPV 45 virus-like particles. Further, this invention relates to pharmaceutical compositions comprising HPV45 VLPs and VLPs of at least one additional HPV type. In a preferred embodiment, the at least one additional HPV type is selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, and HPV68.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or "upstream activating sequences" or inhibiting sequences termed "silencers".

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmids, viruses (including adenovirus), bacteriophages and cosmids.

The designation "45 L1 wild-type sequence" refers to the HPV45 L1 DNA sequence disclosed herein as SEQ ID NO:3 (45 L1 wt). Although the HPV 45 L1 wild-type DNA sequence has been described previously, it is not uncommon to find minor sequence variations between DNAs obtained from clinical isolates. Therefore, a representative 45 L1 wild-type DNA sequence was isolated from clinical samples previously shown to contain HPV 45 DNA (see EXAMPLE 1). The 45 L1 wild-type sequence was used as a reference sequence to compare the codon-optimized 45 L1 sequences disclosed herein (see FIGURE 1).

The designation "HPV 45 L1 R" or "45 L1 R" refers to an exemplary synthetic HPV45 L1 nucleotide sequence (SEQ ID NO:1), disclosed herein, wherein the sequence was rebuilt so that it comprises codons that are preferred for high-level expression by a yeast cell.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

The term "mammalian" refers to any mammal, including a human being.

"VLP" or "VLPs" mean(s) virus-like particle or virus-like particles.

"Synthetic" means that the HPV45 L1 gene was created so that it contains a sequence of nucleotides that is not the same as the sequence of nucleotides present in the designated naturally occurring wild-type HPV45 L1 gene (45 L1 wt, SEQ ID NO:3). As stated above, synthetic molecules are provided herein comprising a sequence of nucleotides comprising codons that are preferred for expression by yeast cells. The synthetic molecules provided herein encode the same amino acid sequence as the wild-type HPV45 L1 gene (SEQ ID NO:2).

## 10 BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a DNA sequence alignment showing nucleotides that were altered in the synthetic HPV45 L1 gene of the present invention (SEQ ID NO:1, indicated as "45 L1 R") (See EXAMPLE 2). The reference sequence is the 45 L1 wild-type sequence (SEQ ID NO:3, indicated as "45 L1 wt"; see EXAMPLE 1). Altered nucleotides are indicated at their corresponding location. Nucleotide number is contained within the parentheses. Identical nucleotides in the 45 L1 rebuilt sequence are indicated with dots.

FIGURE 2 shows the rebuilt synthetic HPV 45 L1 nucleotide and single-code amino acid sequence. Nucleotide number is indicated to the left.

FIGURE 3 shows a Northern blot probed specifically for HPV 45 L1 RNA under high stringency conditions (see EXAMPLE 4). Lane (1) contains 5  $\mu$ g of HPV 45 L1 R RNA and lane (2) contains 10  $\mu$ g of HPV 45 L1 R RNA. A single full-length RNA transcript is apparent on the blot. Arrow on left indicates the predicted position of a full length HPV 45 L1 transcript.

FIGURE 4 shows a Western Blot of HPV 45 L1 wt and three HPV 45 L1 R isolates. Contents of the lanes are: 45 L1 wt (lane 1), 45 L1 R #4 (lane 2), 45 L1 R #7 (lane 3), 45 L1 R #11 (lane 4), HPV 16 L1 control (lane 5). Fifteen micrograms of total yeast protein extract were loaded into each lane of a 10% SDS-PAGE gel. A goat polyclonal anti-serum against a TrpE-HPV 45 L1 fusion protein was used to specifically identify the HPV 45 L1 protein. The arrow at the left indicates the 55 kDa position.

FIGURE 5 shows a portion of the data from two ELISA experiments in ng VLP /  $\mu$ g total protein (see EXAMPLE 7). A comparison between 45 L1 wt and two separate clones of 45 L1 R, is shown. Rebuilt HPV 45 L1 VLP expression was approximately 2 fold higher than the 45 L1 wt.

FIGURE 6 shows a representative sample of HPV 45 VLPs composed of HPV 45 L1 R protein molecules, described herein, as visualized by transmission electron microscopy (see EXAMPLE 8). The bar represents approximately 100 nm.

## DETAILED DESCRIPTION OF THE INVENTION

The majority of cervical carcinomas are associated with infections of specific oncogenic types of human papillomavirus (HPV). The present invention relates to compositions and methods to elicit or enhance immunity to the protein products expressed by genes of oncogenic HPV types.

- 5 Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, which self-assemble into HPV45 virus-like particles (VLPs) and discloses use of said polynucleotides and VLPs in pharmaceutical compositions and vaccines for the prevention and/or treatment of HPV-associated cancer.

The wild-type HPV45 L1 nucleotide sequence has been reported (Genbank Accession # NC\_001590; see also Delius and Hofmann, *Curr. Top. Microbiol. Immunol.* 186: 13-31 (1994)). The  
10 present invention provides synthetic DNA molecules encoding the HPV45 L1 protein. The synthetic molecules of the present invention comprise a sequence of codons, wherein at least a portion of the codons have been altered to use the codons preferred by a yeast cell for high-level expression. The synthetic molecules may be used as a coding sequence for expression of HPV45 L1 protein, which may self-assemble into VLPs. Said VLPs may be used in a VLP-based vaccine to provide effective  
15 immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.

Expression of HPV VLPs in yeast cells offers the advantages of being cost-effective and easily adapted to large-scale growth in fermenters. However, many HPV L1 proteins, including HPV45 L1 are expressed at levels in yeast cells which are lower than what is desirable for commercial scale-up.

20 Accordingly, the present invention relates to HPV45 L1 gene sequences that are "optimized" for high level expression in a yeast cellular environment.

A "triplet" codon of four possible nucleotide bases can exist in over 60 variant forms. Because these codons provide the message for only 20 different amino acids (as well as transcription initiation and termination), some amino acids can be coded for by more than one codon, a phenomenon  
25 known as codon redundancy. For reasons not completely understood, alternative codons are not uniformly present in the endogenous DNA of differing types of cells. Indeed, there appears to exist a variable natural hierarchy or "preference" for certain codons in certain types of cells. As one example, the amino acid leucine is specified by any of six DNA codons including CTA, CTC, CTG, CTT, TTA, and TTG. Exhaustive analysis of genome codon use frequencies for microorganisms has revealed  
30 endogenous DNA of *E. coli* most commonly contains the CTG leucine-specifying codon, while the DNA of yeasts and slime molds most commonly includes a TTA leucine-specifying codon. In view of this hierarchy, it is generally believed that the likelihood of obtaining high levels of expression of a leucine-rich polypeptide by an *E. coli* host will depend to some extent on the frequency of codon use. For example, it is likely that a gene rich in TTA codons will be poorly expressed in *E. coli*, whereas a CTG

rich gene will probably be highly expressed in this host. Similarly, a preferred codon for expression of a leucine-rich polypeptide in yeast host cells would be TTA.

The implications of codon preference phenomena on recombinant DNA techniques are manifest, and the phenomenon may serve to explain many prior failures to achieve high expression levels of exogenous genes in successfully transformed host organisms—a less "preferred" codon may be repeatedly present in the inserted gene and the host cell machinery for expression may not operate as efficiently. This phenomenon suggests that synthetic genes which have been designed to include a projected host cell's preferred codons provide an optimal form of foreign genetic material for practice of recombinant protein expression. Thus, one aspect of this invention is an HPV45 L1 gene that is codon-optimized for high-level expression in a yeast cell. In a preferred embodiment of this invention, it has been found that the use of alternative codons encoding the same protein sequence may remove the constraints on expression of HPV45 L1 proteins by yeast cells.

In accordance with this invention, HPV45 L1 gene segments were converted to sequences having identical translated sequences but with alternative codon usage as described by Sharp and Cowe (Synonymous Codon Usage in *Saccharomyces cerevisiae*. *Yeast* 7: 657-678 (1991)), which is hereby incorporated by reference. The methodology generally consists of identifying codons in the wild-type sequence that are not commonly associated with highly expressed yeast genes and replacing them with optimal codons for high expression in yeast cells. The new gene sequence is then inspected for undesired sequences generated by these codon replacements (e.g., "ATTTA" sequences, inadvertent creation of intron splice recognition sites, unwanted restriction enzyme sites, high GC content, presence of transcription termination signals that are recognized by yeast, etc.). Undesirable sequences are eliminated by substitution of the existing codons with different codons coding for the same amino acid. The synthetic gene segments are then tested for improved expression.

The methods described above were used to create synthetic gene segments for HPV45 L1, resulting in a gene comprising codons optimized for high level expression in a yeast cellular environment. While the above procedure provides a summary of our methodology for designing codon-optimized genes for use in HPV vaccines, it is understood by one skilled in the art that similar vaccine efficacy or increased expression of genes may be achieved by minor variations in the procedure or by minor variations in the sequence.

Accordingly, the present invention relates to a synthetic polynucleotide comprising a sequence of nucleotides encoding an HPV45 L1 protein, or a biologically active fragment or mutant form of an HPV45 L1 protein, the polynucleotide sequence comprising codons optimized for expression in a yeast host cell. Said mutant forms of the HPV45 L1 protein include, but are not limited to: conservative amino acid substitutions, amino-terminal truncations, carboxy-terminal truncations, deletions, or additions. Any such biologically active fragment and/or mutant will encode either a protein or protein



fragment which at least substantially mimics the immunological properties of the HPV45 L1 protein as set forth in SEQ ID NO:2. The synthetic polynucleotides of the present invention encode mRNA molecules that express a functional HPV45 L1 protein so as to be useful in the development of a therapeutic or prophylactic HPV vaccine.

5 One aspect of this invention is a codon-optimized nucleic acid molecule which encodes the HPV45 L1 protein as set forth in SEQ ID NO:2, said nucleic acid molecule comprising a sequence of nucleotides as set forth in SEQ ID NO:1.

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this  
10 specification.

The synthetic HPV45 DNA or fragments thereof constructed through the methods described herein may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant HPV45 L1. Techniques for such  
15 manipulations are fully described by Sambrook et al. (*Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989); *Current Protocols in Molecular Biology*, Ausubel et al., Green Pub. Associates and Wiley-Interscience, New York (1988); *Yeast Genetics: A Laboratory Course Manual*, Rose et al., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1990)), which are hereby incorporated by reference in their entirety.

20 Thus, the present invention relates to a process for expressing an HPV45 L1 protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid encoding an HPV45 L1 protein into a yeast host cell; and (b) culturing the yeast host cell under conditions which allow expression of said HPV45 L1 protein.

The present invention further relates to a process for expressing an HPV45 L1 protein in  
25 a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid encoding an HPV45 L1 protein into a yeast host cell; wherein the nucleic acid molecule is codon-optimized for optimal expression in the yeast host cell and; (b) culturing the yeast host cell under conditions which allow expression of said HPV45 L1 protein.

This invention further relates to a process for expressing an HPV45 L1 protein in a  
30 recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid as set forth in SEQ ID NO:1 into a yeast host cell; and, (b) culturing the yeast host cell under conditions which allow expression of said HPV45 L1 protein.

The synthetic genes of the present invention can be assembled into an expression  
35 cassette that comprises sequences designed to provide efficient expression of the HPV45 L1 protein in the host cell. The cassette preferably contains the synthetic gene, with related transcriptional and

translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is the *S.cerevisiae GAL1* promoter, although those skilled in the art will recognize that any of a number of other known yeast promoters such as the *GAL10*, *GAL7*, *ADH1*, *TDH3*, or *PGK* promoters, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the *S.cerevisiae ADH1* terminator, although other known transcriptional terminators may also be used. The combination of *GAL1* promoter – *ADH1* terminator is particularly preferred.

Another aspect of this invention is an HPV45 virus-like particle (VLP) produced by recombinantly expressing the HPV45 L1 or L1 + L2 genes in a yeast cell, methods of producing HPV45 VLPs, and methods of using HPV45 VLPs. VLPs can self-assemble when L1, the major capsid protein of human and animal papillomaviruses, is expressed in yeast, insect cells, mammalian cells or bacteria (for review, see Schiller and Roden, in *Papillomavirus Reviews: Current Research on Papillomaviruses*; Lacey, ed. Leeds, UK: Leeds Medical Information, pp 101-12 (1996)). Morphologically indistinct HPV VLPs can also be produced by expressing a combination of the L1 and L2 capsid proteins. VLPs are composed of 72 pentamers of L1 in a T=7 icosahedral structure (Baker et al., *Biophys. J.* 60(6): 1445-56 (1991)).

VLPs are morphologically similar to authentic virions and are capable of inducing high titres of neutralizing antibodies upon administration into an animal. Immunization of rabbits (Breitburd et al., *J. Virol.* 69(6): 3959-63 (1995)) and dogs (Suzich et al., *Proc. Natl. Acad. Sci. USA* 92(25): 11553-57 (1995)) with VLPs was shown to both induce neutralizing antibodies and protect against experimental papillomavirus infection. However, because the VLPs do not contain the potentially oncogenic viral genome and can self-assemble when expressed from a single gene, they present a safe alternative to the use of live virus in HPV vaccine development (for review, see Schiller and Hidesheim, *J. Clin. Virol.* 19: 67-74 (2000)).

Marais and colleagues (*J. Med. Virol.* 60: 331-336 (2000)) disclose HPV 45 VLPs, which were produced in insect cells from an HPV45 L1 gene expressed from baculovirus. Expression of VLPs in insect cells is not advantageous for vaccine development because of the high associated costs. Additionally, it is often difficult to scale-up expression of HPV L1 genes in insect cell culture to the large volumes necessary for commercial product development. HPV 45 VLPs produced in yeast cells have not been described. Expression of HPV VLPs in yeast cells offers the advantages of being cost-effective and easily adapted to large-scale growth in fermenters. In addition, the yeast genome can be readily altered to ensure selection of recombinant, transformed yeast with increased growth and expression potential.

Thus, the present invention relates to virus-like particles comprised of recombinant L1 protein or recombinant L1 + L2 proteins of HPV45, wherein the recombinant protein is expressed in a yeast cell.

In a preferred embodiment of the invention, the HPV45 VLPs are produced by  
5 expressing HPV 45 L1 or HPV 45 L1 + L2 in a yeast selected from the group consisting of:  
*Saccharomyces cerevisiae*, *Hansenula polymorpha*, *Pichia pastoris*, *Kluyveromyces fragilis*,  
*Kluyveromyces lactis*, and *Schizosaccharomyces pombe*.

Another aspect of this invention is an HPV45 VLP which comprises an HPV45 L1  
protein produced by expressing a codon-optimized HPV45 L1 gene. In a preferred embodiment of this  
10 aspect of the invention, the codon-optimized HPV45 L1 gene comprises a sequence of nucleotides as set  
forth in SEQ ID NO:1.

Yet another aspect of this invention is a method of producing HPV45 VLPs, comprising:  
(a) transforming yeast with a recombinant DNA molecule encoding HPV45 L1 protein or HPV45 L1 +  
L2 proteins; (b) cultivating the transformed yeast under conditions that permit expression of the  
15 recombinant DNA molecule to produce the recombinant HPV45 protein; and (c) isolating the  
recombinant HPV45 protein to produce HPV45 VLPs.

In a preferred embodiment of this aspect of the invention, the yeast is transformed with a  
codon-optimized HPV45 L1 gene to produce HPV45 VLPs. In a particularly preferred embodiment, the  
codon-optimized HPV45 L1 gene comprises a sequence of nucleotides as set forth in SEQ ID NO:1.

20 This invention also provides a method for inducing an immune response in an animal  
comprising administering HPV45 virus-like particles to the animal. In a preferred embodiment, the  
HPV45 VLPs are produced by a codon-optimized gene.

Yet another aspect of this invention is a method of preventing or treating HPV-  
associated cervical cancer comprising administering to a mammal a vaccine comprising HPV45 VLPs.

25 In a preferred embodiment of this aspect of the invention, the HPV45 VLPs are produced in yeast.

This invention also relates to a vaccine comprising HPV45 virus-like particles (VLPs).

In an alternative embodiment of this aspect of the invention, the vaccine further  
comprises VLPs of at least one additional HPV type. In a preferred embodiment, the at least one  
additional HPV type is selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31,  
30 HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, and HPV68.

In a preferred embodiment of this aspect of the invention, the vaccine further comprises  
HPV16 VLPs.

In another preferred embodiment of the invention, the vaccine further comprises HPV16  
VLPs and HPV18 VLPs.

In yet another preferred embodiment of the invention, the vaccine further comprises HPV6 VLPs, HPV11 VLPs, HPV16 VLPs and HPV18 VLPs.

This invention also relates to pharmaceutical compositions comprising HPV 45 virus-like particles. Further, this invention relates to pharmaceutical compositions comprising HPV45 VLPs and VLPs of at least one additional HPV type. In a preferred embodiment, the at least one additional HPV type is selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, and HPV68.

Vaccine compositions of the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal inhibition of HPV45 infection while minimizing any potential toxicity. In addition, co-administration or sequential administration of other agents may be desirable.

The amount of virus-like particles to be introduced into a vaccine recipient will depend on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 10 µg to 100 µg, and preferably about 20 µg to 60 µg of VLPs is administered directly into muscle tissue. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as alum or Merck aluminum adjuvant, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

#### EXAMPLE 1

##### Determination of a Representative HPV 45 L1 Sequence

The HPV 45 L1 sequence has been described previously (Genbank Accession # NC\_001590; *see* Delius and Hofmann *Curr. Top. Microbiol. Immunol.* 186: 13-31 (1994)). It is not

uncommon, however, to find minor sequence variations between DNAs obtained from clinical isolates.

To determine a representative HPV45 L1 wild-type sequence, DNA was isolated from four clinical samples previously shown to contain HPV 45 DNA. HPV 45 L1 sequences were amplified in a polymerase chain reaction (PCR) using *Taq* DNA polymerase and the following primers: HPV 45 L1 F 5' – C C A C C A C C A C C T A T A T A G G T A T T C – 3' (SEQ ID NO:4) and HPV 45 L1 B 5' – C A A A C A T A C A T A T A T G T G C T A A C A – 3' (SEQ ID NO:5). The amplified products were electrophoresed on agarose gels and visualized by ethidium bromide staining. The ~ 1500 bp L1 bands were excised and DNA purified using the QIA quick PCR purification kit (Qiagen, Hilden, Germany). The DNA was then ligated to a TA cloning vector (Invitrogen Corp., Carlsbad, CA), *E. Coli* was transformed with the ligation mixture and plated on LB agar with ampicillin plus IPTG and X-gal for blue/white colony selection. The plates were inverted and incubated for 16 hours at 37°C.

Colony PCR was performed on eight white colonies originating from each of the four clinical isolates that had been PCR amplified. HPV 45 L1 DNA was PCR-amplified using primers HPV 45 L1 F and HPV 45 L1 B. The specific PCR protocol consisted of 25 cycles of 15 seconds at 98°C (denaturation), 30 seconds at 50°C (annealing) and 2 minutes at 68°C (extension). PCR products were visualized by ethidium bromide staining after agarose gel electrophoresis. Several colonies from each isolate contained L1 bands. The second colony from each isolate was cultured in LB medium with ampicillin, shaking at 37°C for 16 hours. Minipreps were performed to extract plasmid DNA from the colonies.

DNA sequencing was performed on the plasmids containing amplified and cloned HPV 45 L1 DNA from the four clinical isolates. DNA and translated amino acid sequences were compared with one another and the Genbank HPV 45 L1 sequences. Sequence analysis of the four clinical isolates revealed that no sequence was identical to the Genbank sequence. The HPV 45 L1 plasmid from isolate #33 was chosen to be the representative 45 L1 wild-type (wt) sequence and is referred to herein as the "45 L1 wild-type sequence" (SEQ ID NO:3, see FIGURE 1). This sequence contained a nine nucleotide, three amino acid, deletion which maintained the subsequent sequence reading frame, five point mutations resulting in five amino acids changes and eight additional silent point mutations. Amino acids 495-497 in the Genbank sequence are deleted in the 45 L1 wt. Genbank amino acids numbers 23 (S->N), 55 (N->S), 303 (I->T), 357 (S->N), and 356 (Q->H) represent the five amino acids changes (Genbank aa -> 45 L1 wt aa). The 8 silent mutations were distributed throughout the sequence. See FIGURE 1.

The 45 L1 wild-type sequence was amplified using the LS-112 5' – C T C A G A T C T C A C A A A C A A A A T G G C T T T G T G G C G G C C T A G T G A C – 3' (SEQ ID NO:6) and HPV 45 L1 EAS 5' – G A C A G A T C T T A T T T T T T A C T A C G T A T A C G T A C A C G – 3' (SEQ ID NO:7) primers to add *Bgl*II extensions. PCR was performed using *Vent* polymerase. The PCR product was visualized by ethidium bromide staining of an agarose gel. The ~ 1500 bp band was

excised and DNA purified using the QIAEX II gel extraction kit (Qiagen). The PCR product was then digested with *Bgl*III at 37°C for 2 hours and purified using the QIA quick PCR purification kit. The *Bgl*III-digested HPV 45 L1 PCR product was ligated to *Bam*HI-digested pGAL110 (described in Hofmann et al., *Virology* 209: 506-18 (1995)) and *E.coli* DH5 was transformed with the ligation mixture.

5 Colonies were screened by PCR for the HPV 45 L1 insert in the correct orientation. Sequence and orientation were confirmed by DNA sequencing. The selected clone was named pGAL110-HPV 45 L1 #6. This clone was digested with *Pst*I, *Eco*RI and *Hind*III to determine the restriction fragment profile of the HPV 45 L1 gene within the pGAL110 vector. DNA fragments were electrophoresed on agarose gels. The resulting restriction fragment profile was visualized by ethidium  
10 bromide staining and viewed with UV light.

Maxiprep DNA was prepared. *Saccharomyces cerevisiae* cells were made competent by spheroplasting with Glusulase and transformed with pGAL110-HPV 45 L1 #6. The yeast transformation mixture was plated in Leu(-) sorbitol top-agar onto Leu(-) sorbitol plates and incubated inverted for 5-7 days at 30°C. Colonies were picked and streaked for clonal isolation on Leu(-) sorbitol plates. Isolated  
15 colonies were subsequently grown in 5 ml of 5 X Leu(-) Ade(-) sorbitol with 1.6% glucose and 4% galactose in rotating tube cultures at 30°C to induce L1 transcription and protein expression.

## EXAMPLE 2

### Yeast codon optimization

20 Yeast-preferred codons have been described (Sharp, Paul M and Cowe, Elizabeth 1991 Synonymous Codon Usage in *Saccharomyces cerevisiae* YEAST 7: 657-678). Expression of the HPV 45 L1 wt protein was detectable; however, to obtain the increased expression necessary for commercial product development, the HPV 45 L1 gene was rebuilt utilizing yeast-preferred codons. Said rebuilt sequence would provide increased HPV45 L1 expression, which would be a significant advance over the  
25 wild-type for use in vaccine development. When the sequence was rebuilt utilizing yeast-optimized codon sequences, the nucleotide sequence of 45 L1 wt was altered at 392 positions to produce 45 L1 R (R = rebuild). The amino acid sequence, however, was not altered. The nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of HPV 45 L1 R are shown in FIGURE 2.

The strategy employed for the gene rebuild was to design long overlapping sense and  
30 antisense oligomers that span the gene, substituting nucleotides with yeast-preferred codon sequences while maintaining the original amino acid sequence. These oligomers were used in place of template DNA in a PCR reaction. Additional amplification primers were designed and used to amplify the rebuilt sequences from the template oligomers. *Pfu* DNA polymerase was used in the PCR of 25 cycles.

The optimal conditions for amplification were section-specific, however most employed  
35 a program resembling 94°C for 5 minutes (denaturing) followed by 25 cycles of 95°C for 30 sec

(denature), 55-50°C for 30 sec (anneal), and 72°C for 1.5 minute (extension), followed by a 7 minute final extension at 72°C and 4°C hold. PCR products were examined by agarose gel electrophoresis. Bands of the appropriate size were excised and DNA gel purified. The amplified fragments were then used as template to assemble the 1533 nt rebuilt HPV 45 L1 gene.

5                   Following rebuild, the 1533 nt band was gel purified, ligated to pCR4 Blunt (Invitrogen) and *E. coli* TOP10 cells were transformed with the ligation mixture. Colonies were grown in 4 ml LB with ampicillin and plasmid DNA was extracted by standard miniprep techniques. The plasmid DNA was sequenced to confirm the presence of the desired changes for the 45 L1 rebuild. The 45 L1 R (rebuild) was re-amplified from pCR4Blunt-45 L1 R to add *Bam*HI extensions to both ends plus a yeast  
10 5'-non-translated leader sequence upstream of the ATG initiation codon. The amplified fragment was cloned as above and plasmid DNA was sequenced. The plasmid, pCR4 Blunt-45 L1 R (*Bam*), was digested with *Bam*HI and DNA fragments were electrophoresed on an agarose gel. The ~1550 bp 45 L1 R (*Bam*) fragment was gel purified, ligated to *Bam*HI-digested pGAL110 and transformed into TOP10F' *E. coli* (Invitrogen).

15                   Colonies were screened by PCR for the HPV 45 L1 R insert in the correct orientation in pGAL110. Sequence and orientation were confirmed by DNA sequencing. Maxiprep plasmid DNA was prepared and used for the transformation of *S. cerevisiae* cells which had been made competent by spheroplasting. The transformed yeast were plated in Leu(-) sorbitol top-agar onto Leu(-) sorbitol plates, which were incubated inverted for 7 days. Colonies were streaked for clonal isolation on Leu(-) sorbitol  
20 plates. Isolated colonies were subsequently grown in 5 ml of 5 X Leu(-) Ade(-) sorbitol with 1.6% glucose and 4% galactose in rotating tube cultures at 30°C to induce L1 transcription and protein expression. After 48 hours, a culture volume equivalent to an OD<sub>600</sub> = 10 was pelleted, the supernatant was removed and the pellets were frozen and stored at -70°C.

### 25                   EXAMPLE 3

#### RNA preparation

Cell pellets of transformed yeast induced to express HPV 45 L1 by galactose induction were thawed on ice, suspended in 0.8 ml of Trizol reagent (Life Technologies, Gibco BRL) and incubated at room temperature for 5 minutes. One fifth volume of chloroform was added to the vial. It  
30 was then shaken vigorously for 15 seconds to mix and incubated at room temperature for 3 minutes. After a 5 minute centrifugation at 13 k rpms, the upper phase was collected and transferred to a new vial. 0.4 ml isopropanol was added and incubated at room temperature for 10 minutes. Centrifugation to pellet the RNA was performed at 13 k rpms for 10 minutes. The supernatant was decanted, the RNA pellet washed with 75% EtOH and centrifugation repeated. The supernatant was decanted and the RNA  
35 pellet allowed to air dry for 15 minutes followed by suspension in RNase-free water. Spectrophotometry

was performed to determine the concentration of RNA in the sample using the assumption that an A<sub>260</sub> reading of 1 = 40 µg/ml RNA when the A<sub>260</sub>/A<sub>280</sub> is 1.7-2.0.

#### EXAMPLE 4

##### 5 Northern Blot Analysis

A 1.1% agarose formaldehyde gel was cast. Five and ten micrograms of RNA was combined with denaturing buffer (final concentrations: 6% formaldehyde, 50% formamide and 0.1 x MOPS) and heated to 65°C for 10 minutes. A one-tenth volume of gel loading buffer was added and the sample loaded onto the gel. Electrophoresis was performed at 75 volts in 1 x MOPS buffer for ~ 3 hours.

10 The gel was washed for 60 minutes in 10 x SSC.

The RNA was transferred to a Hybond-N+ nylon membrane (Amersham Biosciences, Piscataway, NJ) by capillary action over 16 hours in 10 x SSC. The RNA was then fixed to the nylon membrane by cross-linking using the Stratagene UV Stratalinker (Stratagene, La Jolla, CA) auto-crosslink function. After fixing, the nylon membrane was allowed to air dry.

15 The Roche DIG High Prime DNA Labeling and Detection Kit I (F. Hoffmann-La Roche Ltd., Basel, Switzerland) was used to label 45 L1 R DNA sequences with DIG to be used as a probe to detect 45 L1 R RNA on the Northern blot. The pre-hybridization, hybridization and immunological development using an anti-DIG alkaline phosphatase conjugated antibody were performed per the manufacturer's recommendations. Briefly, the blot was pre-hybridized at 37°C for 30 minutes with  
20 gentle shaking. The probe was denatured by heating to 95°C for 5 minutes and quenching on ice. The probe was added to the hybridization solution and applied to the membrane for 4 hours at 44.6°C with gentle shaking. The hybridization solution was then removed and the blot washed twice for 5 minutes in 2 x SSC with 0.1% SDS at room temperature, followed by an additional wash at 65°C with 0.5 x SSC and 0.1% SDS. The blot was then blocked for 30 minutes and anti-DIG alkaline phosphatase conjugated  
25 antibody applied at a 1:5000 dilution for 30 minutes. The blot was washed and the presence of probe bound RNA determined by NBT/BCIP substrate detection of the alkaline phosphatase conjugated anti-DIG bound antibody.

Initial analysis of yeast expressing 45 L1 wt suggested that there was functional HPV 45 L1 transcription and translation; however, the sequence was rebuilt with yeast-preferred codon sequences  
30 to obtain an increased level of expression, useful for vaccine development. The rebuilt 45 L1 sequence was engineered to omit any possible premature transcription termination sites to ensure robust transcription. Northern blot analysis of the 45 L1 R transcript revealed that full-length transcripts were generated (FIGURE 3).

35

#### EXAMPLE 5



### HPV 45 L1 Protein Expression

Frozen yeast cell pellets of galactose-induced cultures equivalent to OD<sub>600</sub>= 10, were thawed on ice and suspended in 300 µl of PC buffer (100 mM Na<sub>2</sub>HPO<sub>4</sub> and 0.5 M NaCl, pH 7.0) with 2mM PMSF. Acid-washed 0.5mm glass beads, were added, ~ 0.5g/tube. The tubes were vortexed for 3 cycles of 5 minutes at 4°C with a 1 minute break. 7.5 µl of 20% TritonX100 was added and vortex repeated for 5 minutes at 4°C. The tubes were placed on ice for 15 minutes, and then centrifuged for 10 minutes at 4°C. The supernate was transferred to a sterile microfuge tube, labeled as total yeast protein extract, dated and stored at -70°C.

### EXAMPLE 6

#### Western Blot Analysis

Total yeast protein extract from twenty isolated yeast colonies for each 45 L1 construct were analyzed by Western blot to confirm expression of 45 L1 protein after galactose induction.

Ten micrograms of total yeast protein extract was combined with SDS-PAGE loading buffer and heated to 95°C for 10 minutes. The proteins were loaded onto a 10% SDS-PAGE gel and electrophoresed in Tris-Glycine buffer. After protein separation, the proteins were Western transferred from the gel to nitrocellulose and the blot blocked in 1 x diluent buffer (Kirkegaard and Perry Laboratories) for 1 hour at room temperature with rocking. The blot was washed three times and then incubated with a 1:2500 dilution of goat anti-trpE-HPV 45 L1 serum at room temperature for 16 hours. The blot was then washed three times and incubated with a 1:2500 dilution of anti-goat-HRP conjugated antibody for 1 hr. The blot was again washed three times and NBT/BCIP detection substrate applied (Kirkegaard and Perry Laboratories). Immunoreactive proteins were detected as purple bands on the blot.

The results demonstrate that in all cases, the 45 L1 protein was detected as a distinct immunoreactive band on the nitrocellulose corresponding to approximately 57 kDa (FIGURE 4). The 16 L1 protein, which is approximately 55 kDa, was included as a positive control, along with HPV L1-free total yeast protein extract as a negative control (data not shown).

### EXAMPLE 7

#### ELISA Assay

The yeast cells expressing HPV 45 L1 were grown by a variety of methods including rotating tube cultures, shake flasks and fermenters. The yeast were lysed and protein extracts were made to determine the amount of HPV 45 L1 virus-like particles (VLPs) produced per microgram of total protein. A sandwich ELISA was designed to demonstrate HPV 45 L1 VLP expression.

The H18R.5 monoclonal antibody (mAb), which recognizes both HPV type 18 and 45 L1 VLPs, was used to bind the 45 L1 VLPs found in the yeast protein extracts. The unbound proteins were washed away and H45.10B11.A5, an HPV 45 L1 VLP type and conformational specific mAb, was applied as a detection antibody. True, conformationally correct, 45 L1 VLPs were bound and detection was facilitated by the use of an anti-mouse IgG1 HRP-conjugated antibody and TMB substrate.

Specifically, H18R.5 was used to coat the bottom of Immulon 4 HBX 96 well plates overnight at 4°C. The plates were washed three times with PBS and 0.05% Tween 20, followed by blocking with blocking solution (PBS + 0.05% Tween 20 + 1% BSA). The plates were washed three times and antigens (total yeast cell lysates diluted in blocking solution to 100 µg/ml), were applied to row A in duplicate. Reference standards of purified HPV 45 L1 VLPs were applied to row A columns 1 and 2 at 3300ng/ml in 100 µg/ml total yeast protein. The reference and test samples were then serially diluted two-fold down each column. After three hours at room temperature the excess antigen was removed by aspiration and the plates washed 3 times. Cell supernatant containing HPV 45 L1 VLP conformational specific mAb H45.10B11.A5 was diluted 1:80 in blocking solution and applied to each well for an hour at room temperature. The plates were washed three times and an anti-mouse IgG1 HRP-conjugated antibody diluted 1:8000 in blocking solution was applied for 1 hour at room temperature. The plates were washed and TMB (Pierce) applied for 5 minutes to detect HRP-conjugated antibody complexes. The detection reaction was stopped by the addition of 2M H<sub>2</sub>SO<sub>4</sub>. Plates were read at 450 nm wavelength and the concentration of HPV 45 L1 VLP was determined by comparison to the reference standards in ng VLP / µg total protein.

A comparison between 45 L1 wt and two separate clones of 45 L1 R, all assayed in duplicate, is shown in FIGURE 5. Rebuilt HPV 45 L1 VLP expression was approximately 2 fold higher than the results observed for 45 L1 wt (FIGURE 6).

## EXAMPLE 8

### Transmission Electron Microscopy

To demonstrate that the 45 L1 protein was in fact self-assembling to form pentameric-L1 capsomers, which in turn self-assemble into virus-like particles, a partially purified 45 L1 R protein extract was analyzed by transmission EM.

Yeast cells were grown under small scale fermentation conditions, pelleted and the pellets were subjected to purification treatments. Pellet and clarified yeast extracts were analyzed by immunoblot to demonstrate L1 protein expression and retention through the purification procedure. Clarified yeast extracts were then subjected to centrifugation over a 45%-sucrose cushion and the resulting pellet suspended in buffer for analysis by transmission electron microscopy (EM).

A representative sample of the 45 L1 R VLPs produced is shown in FIGURE 6. The diameter of the spherical particles in this crude sample ranged from between 40 and 60 nm with some particles displaying a regular array of capsomers.

## WHAT IS CLAIMED IS:

1. A nucleic acid molecule comprising a sequence of nucleotides that encodes an HPV45 L1 protein as set forth in SEQ ID NO:2, the nucleic acid sequence being codon-optimized for high-level expression in a yeast cell.
2. A vector comprising the nucleic acid molecule of claim 1.
3. A host cell comprising the vector of claim 3.
4. The host cell of claim 3, wherein the host cell is selected from the group consisting of: *Saccharomyces cerevisiae*, *Hansenula polymorpha*, *Pichia pastoris*, *Kluyveromyces fragilis*, *Kluyveromyces lactis*, and *Schizosaccharomyces pombe*.
5. The host cell of claim 4, wherein the host cell is *Saccharomyces cerevisiae*.
6. The nucleic acid molecule of claim 1, wherein the sequence of nucleotides comprises a sequence of nucleotides as set forth in SEQ ID NO:1.
7. A vector comprising the nucleic acid molecule of claim 6.
8. A host cell comprising the vector of claim 7.
9. Virus-like particles (VLPs) comprised of recombinant L1 protein or recombinant L1 + L2 proteins of HPV45, wherein the recombinant L1 protein or the recombinant L1 + L2 proteins are produced in yeast.
10. The VLPs of claim 9, wherein the recombinant L1 protein or recombinant L1 + L2 proteins are encoded by a codon-optimized HPV45 L1 nucleic acid molecule.
11. The VLPs of claim 10, wherein the codon-optimized nucleic acid molecule consists essentially of a sequence of nucleotides as set forth in SEQ ID NO:1.
12. A method of producing the VLPs of Claim 10, comprising:

(a) transforming yeast with a codon-optimized DNA molecule encoding HPV45 L1 protein or HPV45 L1 + L2 proteins;

(b) cultivating the transformed yeast under conditions that permit expression of the codon-optimized DNA molecule to produce a recombinant papillomavirus protein; and

(c) isolating the recombinant papillomavirus protein to produce the VLPs of Claim 10.

13. A vaccine comprising the VLPs of Claim 10.

14. Pharmaceutical compositions comprising the VLPs of claim 10.

15. A method of preventing HPV infection comprising administering the vaccine of Claim 13 to a mammal.

16. A method for inducing an immune response in an animal comprising administering the VLPs of Claim 10 to an animal.

17. The virus-like particles of Claim 10 wherein the yeast is selected from the group consisting of *Saccharomyces cerevisiae*, *Hansenula polymorpha*, *Pichia pastoris*, *Kluyveromyces fragilis*, *Kluyveromyces lactis*, and *Schizosaccharomyces pombe*.

18. The virus-like particles of claim 17, wherein the yeast is *Saccharomyces cerevisiae*.

19. The vaccine of claim 13, further comprising VLPs of at least one additional HPV type.

20. The vaccine of claim 19, wherein the at least one additional HPV type is selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, and HPV68.

21. The vaccine of claim 20, wherein the at least one HPV type comprises HPV16.

22. The vaccine of claim 21, further comprising HPV18 VLPs.

23. The vaccine of claim 22, further comprising HPV6 VLPs and HPV11 VLPs.
24. The vaccine of claim 23, further comprising HPV31 VLPs.
- 5 25. The vaccine of claim 22, further comprising HPV31 VLPs.

1/10

## HPV 45 L1 Nucleotide Sequence Alignment

45 L1 wt	( 1)	ATGGCTTTGTGGCGGCCTAGTGACAGTACGGTATATCTTCCACCACCTTC
45 L1 R	( 1)	.....A.A..ATC....TC...T..C..CT.G.....A..
45 L1 wt	( 51)	TGTGGCCAGAGTTGTCAACACTGATGATTATGTGTCTCGCACAAGCATAT
45 L1 R	( 51)	...C..T.....C.....C..C..C..C..CA.A..CTC...C.
45 L1 wt	( 101)	TTTACCATGCAGGCAGTTCCTCGATTATTAAGTGTAGGCAATCCATATTTT
45 L1 R	( 101)	.C.....C..T..TTC....A....G..G.....C..T..C.....C..C
45 L1 wt	( 151)	AGGGTTGTACCTAGTGGTGCAGGTAATAAACAGGCTGTTCTAAGGTATC
45 L1 R	( 151)	..A..C..C..ATCC.....T.....C..G..A.....A.....C..
45 L1 wt	( 201)	CGCATATCAGTATAGGGTGTTTAGAGTAGCTTTGCCCGATCCTAATAAAT
45 L1 R	( 201)	T..T..C..A..C..A..C..C.....C.....A..C..A..C..G.
45 L1 wt	( 251)	TTGGATTACCTGATTCTACTATATATAATCCTGAAACACAACGTTTGGTT
45 L1 R	( 251)	.C..T..G..A..C.....C..C..C..A.....T...A.A.....C
45 L1 wt	( 301)	TGGGCATGTGTAGGTATGGAAATTGGTCGTGGGCAGCCTTTAGGTATTGG
45 L1 R	( 301)	.....C..C.....C...A.A..T..A..A..G.....C..
45 L1 wt	( 351)	CCTAAGTGGCCATCCATTTTATAATAAATTGGATGATACAGAAAGTGCTC
45 L1 R	( 351)	TT.GTC...T..C.....C..C..C..G.....C..C..C...TCC....
45 L1 wt	( 401)	ATGCAGCTACAGCTGTTATTACGCAGGATGTTAGGGATAATGTGTCAGTT
45 L1 R	( 401)	.C..T.....T.....C..C..T..A..C..C..A..C..C..C..T..C
45 L1 wt	( 451)	GATTATAAGCAAACACAGCTGTGTATTTTAGGTTGTGTACCTGCTATTGG
45 L1 R	( 451)	..C..C.....C..AT.....C..G.....C..A.....C..
45 L1 wt	( 501)	TGAGCACTGGGCCAAGGGCACACTTTGTAAACCTGCACAATTGCAACCTG
45 L1 R	( 501)	...A.....T.....T..CT.G.....G..A..T.....A.
45 L1 wt	( 551)	GTGACTGTCCTCCTTTGGAACCTAAAAACACCATTATTGAGGATGGTGAT
45 L1 R	( 551)	.....A..A.....T.G..G.....T..C..C..A..C.....C

FIG. 1A

2/10

45 L1 wt	( 601)	ATGGTGGATACAGGTTATGGGGCAATGGATTTTAGTACATTGCAGGATAC
45 L1 R	( 601)	.....T..C..T.....C..T..T.....C..CTCC..CC.....C..
45 L1 wt	( 651)	AAAGTGCGAGGTTCCATTAGACATTTGTCAATCCATCTGTAAATATCCAG
45 L1 R	( 651)	T.....T..A.....G.....C.....T.....G..C....
45 L1 wt	( 701)	ATTATTTGCAAATGTCTGCTGATCCCTATGGGGATTCTATGTTTTTTTGC
45 L1 R	( 701)	.C..C.....C.....C..A..C..T..C.....C..C..T
45 L1 wt	( 751)	CTACGCCGTGAACAACCTGTTTGCAAGACATTTTGGGAATAGGGCAGGTGT
45 L1 R	( 751)	T.GA.AA.A.....T....C..T.....C..C.....C..A..T.....
45 L1 wt	( 801)	TATGGGTGACACAGTACCTACAGACCTATATATTAAAGGCACTAGCGCTA
45 L1 R	( 801)	C.....T..T..A..T...T.G..C..C..G..T..CTCT....
45 L1 wt	( 851)	ATATGCGTGAAACCCCTGGCAGTTGTGTGTATTCCCCTTCTCCAGTGGC
45 L1 R	( 851)	.C...A.A.....T..A..TTCC.....C..C..T..A.....ATC...T
45 L1 wt	( 901)	TCTATTACTACTTCTGATTCTCAATTATTTAATAAGCCATATTGGTTACA
45 L1 R	( 901)	.....C.....C..C.....G..C..C.....C.....G..
45 L1 wt	( 951)	TAAGGCCCCAGGGCCATAACAATGGTATTTGTTGGCATAATCAGTTGTTTG
45 L1 R	( 951)	C.....T..A..T..C.....C.....C.....C..C..A.....C..
45 L1 wt	(1001)	TTACTGTAGTGGACACTACCCGCAGTACTAATTTAACATTATGTGCCTCT
45 L1 R	(1001)	.C..C..C..T.....A.ATC.....C..G..C..G.....T...
45 L1 wt	(1051)	ACACAAAATCCTGTGCCAAATACATATGATCCTACTAAGTTTAAGCACTA
45 L1 R	(1051)	..T.....C..A..T.....C..T..C..C..A..C.....C.....
45 L1 wt	(1101)	TAGTAGACATGTGGAGGAATATGATTTACAGTTTATTTTTCAGTTGTGCA
45 L1 R	(1101)	CTCC.....C..C.....C..C..G..A..C..C..C..A.....T..
45 L1 wt	(1151)	CTATTACTTTAACTGCAGAGGTTATGTCATATATCCATAGTATGAATAGT
45 L1 R	(1151)	....C..C..G..C..T..A..C.....C..C..T..CTC.....CTCC
45 L1 wt	(1201)	AGTATATTGGAAAATTGGAATTTTGGTGTACCTCCACCACCTACTACAAG
45 L1 R	(1201)	TC...C.....C.....C..C.....T..A.....A..C..CTC

FIG. 1B



3/10

45 L1 wt	(1251)	TTTAGTGGATACATATCGTTTTGTGCAATCAGTTGCTGTTACCTGTCAAA
45 L1 R	(1251)	C..G..T..C..T..CA.A..C..C.....T..C.....C..T.....
45 L1 wt	(1301)	AGGATACTACACCTCCAGAAAAGCAGGATCCATATGATAAATTAAAGTTT
45 L1 R	(1301)	....C..C..T..A.....A..C.....C..C..G..G.....C
45 L1 wt	(1351)	TGGACTGTTGACCTAAAGGAAAAATTTTCCTCCGATTTGGATCAATATCC
45 L1 R	(1351)	.....T.G.....G..C..T.....C.....C.....C..
45 L1 wt	(1401)	CCTTGGTCGAAAGTTTTTAGTTTCAGGCTGGGTTACGTCGTAGGCCTACCA
45 L1 R	(1401)	AT.G...A.....C..G.....A.....T..GA.A.....A..A..T.
45 L1 wt	(1451)	TAGGACCTCGTAAGCGTCCTGCTGCTTCCACGTCTACTGCATCTAGGCCT
45 L1 R	(1451)	.C..T..A.....A..A.....T..C.....T.....A..A
45 L1 wt	(1501)	GCCAAACGTGTACGTATACGTAGTAAAAAATAA (SEQ ID NO:3)
45 L1 R	(1501)	..T..G.....CA.A..CA.ATCC..G..G...(SEQ ID NO:1)

FIG.1C

4/10

## Synthetic HPV 45 L1 Nucleotide and Amino Acid Sequences

M A L W R P S D S T V Y L P P P S  
1 ATGGCTTTGT GGAGACCATC TGACTCTACT GTCTACTTGC CACCACCATC  
TACCGAAACA CCTCTGGTAG ACTGAGATGA CAGATGAACG GTGGTGGTAG  
V A R V V N T D D Y V S R T S I F  
51 TGTCGCTAGA GTCGTCAACA CTGACGACTA CGTCTCCAGA ACCTCCATCT  
ACAGCGATCT CAGCAGTTGT GACTGCTGAT GCAGAGGTCT TGGAGGTAGA  
Y H A G S S R L L T V G N P Y F  
101 TCTACCACGC TGGTTCTTCC AGATTGTTGA CTGTCGGTAA CCCATACTTC  
AGATGGTGCG ACCAAGAAGG TCTAACAAC TACAGCCATT GGGTATGAAG  
R V V P S G A G N K Q A V P K V S  
151 AGAGTCGTCC CATCCGGTGC TGGTAACAAG CAAGCTGTTC CAAAGGTCTC  
TCTCAGCAGG GTAGGCCACG ACCATTGTTC GTTCGACAAG GTTTCCAGAG  
A Y Q Y R V F R V A L P D P N K F  
201 TGCTTACCAA TACAGAGTCT TCAGAGTCGC TTTGCCAGAC CCAAACAAGT  
ACGAATGGTT ATGTCTCAGA AGTCTCAGCG AAACGGTCTG GGTTTGTTCA  
G L P D S T I Y N P E T Q R L V  
251 TCGGTTTGCC AGACTCTACT ATCTACAACC CAGAAACTCA AAGATTGGTC  
AGCCAAACGG TCTGAGATGA TAGATGTTGG GTCTTTGAGT TTCTAACCAG  
W A C V G M E I G R G Q P L G I G  
301 TGGGCATGCG TCGGTATGGA AATCGGTAGA GGTCAACCAT TGGGTATCGG  
ACCCGTACGC AGCCATACCT TTAGCCATCT CCAGTTGGTA ACCCATAGCC  
L S G H P F Y N K L D D T E S A H  
351 TTTGTCTGGT CACCCATTCT ACAACAAGTT GGACGACACC GAATCCGCTC  
AAACAGACCA GTGGGTAAGA TGTTGTTCAA CCTGCTGTGG CTTAGGCGAG  
A A T A V I T Q D V R D N V S V  
401 ACGCTGCTAC TGCTGTCATC ACTCAAGACG TCAGAGACAA CGTCTCTGTC  
TGCGACGATG ACGACAGTAG TGAGTTCTGC AGTCTCTGTT GCAGAGACAG  
D Y K Q T Q L C I L G C V P A I G  
451 GACTACAAGC AAACCAATT GTGTATCTTG GGTGTGTCC CAGCTATCGG  
CTGATGTTTCG TTTGGGTAA CACATAGAAC CCAACACAGG GTCGATAGCC  
E H W A K G T L C K P A Q L Q P G  
501 TGAACACTGG GCTAAGGGTA CCTTGTGTAA GCCAGCTCAA TTGCAACCAG  
ACTTGTGACC CGATTCCCAT GGAACACATT CGGTCGAGTT AACGTTGGTC

FIG.2A

5/10

D C P P L E L K N T I I E D G D  
551 GTGACTGTCC ACCATTGGAA TTGAAGAACA CTATCATCGA AGACGGTGAC  
CACTGACAGG TGGTAACCTT AACTTCTTGT GATAGTAGCT TCTGCCACTG  
M V D T G Y G A M D F S T L Q D T  
601 ATGGTTGACA CTGGTTACGG TGCTATGGAC TTCTCCACCC TGCAGGACAC  
TACCAACTGT GACCAATGCC ACGATACCTG AAGAGGTGGG ACGTCCTGTG  
K C E V P L D I C Q S I C K Y P D  
651 TAAGTGTGAA GTTCCATTGG ACATCTGTCA ATCTATCTGT AAGTACCCAG  
ATTCACACTT CAAGGTAACC TGTAGACAGT TAGATAGACA TTCATGGGTC  
Y L Q M S A D P Y G D S M F F C  
701 ACTACTTGCA AATGTCCGCT GACCCATACG GTGACTCTAT GTTCTTCTGT  
TGATGAACGT TTACAGGCGA CTGGGTATGC CACTGAGATA CAAGAAGACA  
L R R E Q L F A R H F W N R A G V  
751 TTGAGAAGAG AACAAATTGTT CGCTAGACAC TTCTGGAACA GAGCTGGTGT  
AACTCTTCTC TTGTTAACAA GCGATCTGTG AAGACCTTGT CTCGACCACA  
M G D T V P T D L Y I K G T S A N  
801 CATGGGTGAC ACTGTTCCAA CTGACTTGTA CATCAAGGGT ACCTCTGCTA  
GTACCCACTG TGACAAGGTT GACTGAACAT GTAGTTCCCA TGGAGACGAT  
M R E T P G S C V Y S P S P S G  
851 ACATGAGAGA AACTCCAGGT TCCTGTGTCT ACTCTCCATC TCCATCTGGT  
TGTA CTCTCT TTGAGGTCCA AGGACACAGA TGAGAGGTAG AGGTAGACCA  
S I T T S D S Q L F N K P Y W L H  
901 TCTATCACTA CTTCCGACTC TCAATTGTTC AACAAGCCAT ACTGGTTGCA  
AGATAGTGAT GAAGGCTGAG AGTTAACAAG TTGTTCCGTA TGACCAACGT  
K A Q G H N N G I C W H N Q L F V  
951 CAAGGCTCAA GGTCACAACA ACGGTATCTG TTGGCACAAC CAATTGTTCTG  
GTTCCGAGTT CCAGTGTTGT TGCCATAGAC AACCGTGTTG GTTAACAAGC  
T V V D T T R S T N L T L C A S  
1001 TCACCGTCGT TGACACTACC AGATCTACTA ACTTGACCTT GTGTGCTTCT  
AGTGGCAGCA ACTGTGATGG TCTAGATGAT TGAAGTGAA CACACGAAGA  
T Q N P V P N T Y D P T K F K H Y  
1051 ACTCAAACCC CAGTTCCAAA CACTTACGAC CCAACCAAGT TCAAGCACTA  
TGAGTTTTGG GTCAAGGTTT GTGAATGCTG GGTTGGTTCA AGTTCGTGAT  
S R H V E E Y D L Q F I F Q L C T  
1101 CTCCAGACAC GTCGAGGAAT ACGACTTGCA ATTCATCTTC CAATTGTGTA  
GAGGTCTGTG CAGCTCCTTA TGCTGAACGT TAAGTAGAAG GTTAACACAT  
I T L T A E V M S Y I H S M N S  
1151 CTATCACCTT GACCGCTGAA GTCATGTCCT ACATTCCTC TATGAAGTCC  
GATAGTGGAA CTGGCGACTT CAGTACAGGA TGTAAGTGAG ATACTTGAGG

FIG.2B

6/10

S I L E N W N F G V P P P P T T S  
1201 TCTATCTTGG AAAACTGGAA CTTCGGTGTT CCACCACCAC CAACCACCTC  
AGATAGAACC TTTTGACCTT GAAGCCACAA GGTGGTGGTG GTTGGTGGAG  
L V D T Y R F V Q S V A V T C Q K  
1251 CTTGGTTGAC ACTTACAGAT TCGTCCAATC TGTCGCTGTC ACTTGTCAAA  
GAACCAACTG TGAATGTCTA AGCAGGTTAG ACAGCGACAG TGAACAGTTT  
D T T P P E K Q D P Y D K L K F  
1301 AGGACACCAC TCCACCAGAA AAGCAAGACC CATACGACAA GTTGAAGTTC  
TCCTGTGGTG AGGTGGTCTT TTCGTTCTGG GTATGCTGTT CAACTTCAAG  
W T V D L K E K F S S D L D Q Y P  
1351 TGGACTGTTG ACTTGAAGGA AAAGTTCTCT TCCGACTTGG ACCAATACCC  
ACCTGACAAC TGAAC TTCCT TTTCAAGAGA AGGCTGAACC TGGTTATGGG  
L G R K F L V Q A G L R R R P T I  
1401 ATTGGGTAGA AAGTTCTTGG TTCAAGCTGG TTTGAGACGT AGACCAACTA  
TAACCCATCT TTCAAGAACC AAGTTCGACC AAACTCTGCA TCTGGTTGAT  
G P R K R P A A S T S T A S R P  
1451 TCGGTCCACG TAAGAGACCA GCTGCTTCCA CTTCCACTGC TTCTAGACCA  
AGCCAGGTGC ATTCTCTGGT CGACGAAGGT GAAGGTGACG AAGATCTGGT  
A K R V R I R S K K \* (SEQ ID NO:2)  
1501 GCTAAGCGTG TCAGAATCAG ATCCAAGAAG TAA (SEQ ID NO:1)  
CGATTCGCAC AGTCTTAGTC TAGGTTCTTC ATT (SEQ ID NO:8)

FIG.2C

7/10

NORTHERN BLOT ANALYSIS OF HPV 45 L1 R.




FIG.3

8/10




FIG.4

9/10

## ELISA ASSAY

L1 CONSTRUCT	ng VLP/mcg TOTAL PROTEIN	FOLD INCREASE OVER WILD-TYPE
45 L1 WILD-TYPE	5 ng VLP/mcg TOTAL PROTEIN	na
45 L1 ISOLATE #4	12 ng VLP/mcg TOTAL PROTEIN	2.4
45 L1 R ISOLATE #11	10 ng VLP/mcg TOTAL PROTEIN	2.0

FIG.5

10/10

TRANSMISSION EM OF VLPs COMPOSED OF HPV  
45 L1 R PROTEIN MOLECULES.




FIG.6



## SEQUENCE LISTING

<110> Merck & Co., Inc.  
 Bryan, Janine T.  
 Brownlow, Michelle K.  
 Schultz, Loren D.  
 Jansen, Kathrin U.

<120> OPTIMIZED EXPRESSION OF HPV 45 L1 IN  
 YEAST

<130> 21500-PCT

<150> 60/506,812

<151> 2003-09-29

<160> 8

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1533

<212> DNA

<213> Artificial Sequence

<220>

<223> HPV45 L1R

<400> 1

```

atggcctttgt ggagaccatc tgactctact gtctacttgc caccaCcatc tgtecgctaga 60
gtcgtcaaca ctgacgacta cgtctccaga acctccatct tctaccacgc tggttcttcc 120
agattgttga ctgtcggtaa cccatacttc agagtcgtcc catccggtgc tggtaacaag 180
caagctgttc caaaggcttc tgcttaccaa tacagagtct tcagagtcgc tttgccagac 240
ccaaacaagt tcggtttgcc agactctact atctacaacc cagaaactca aagattgggtc 300
tgggcatgcg tcggtatgga aatcggtaga ggtcaaccat tgggtatcgg tttgtctgggt 360
caccattctt acaacaagtt ggacgacacc gaatccgctc acgctgctac tgctgtcatc 420
actcaagacg tcagagacaa cgtctctgtc gactacaagc aaaccCaatt gtgtatcttg 480
ggttgtgtcc cagctatcgg tgaacactgg gctaagggta ccttgtgtaa gccagctcaa 540
ttgcaaccag gtgactgtcc accattggaa ttgaagaaca ctatcatcga agacgggtgac 600
atgggttgaca ctggttacgg tgctatggac ttctccacc tgaggacac taagtgtgaa 660
gttccattgg acatctgtca atctatctgt aagtaccag actacttgca aatgtccgct 720
gaccatacgt gtgactctat gttcttctgt ttgagaagag aacaatttgtt cgctagacac 780
ttctggaaca gagctggtgt catgggtgac actgttccaa ctgacttgta catcaaggggt 840
acctctgcta acatgagaga aactccaggt tcctgtgtct actctccatc tccatctggt 900
tctatcata cttccgactc tcaattgttc aacaagccat actggttgca caaggctcaa 960
ggtcacaaca acggtatctg ttggcacaac caattgttcg tcaccgtcgt tgacactacc 1020
agatctacta acttgacctt gtgtgcttct actcaaaacc cagttccaaa cacttacgac 1080
ccaaccaagt tcaagcacta ctccagacac gtcgaggaat acgacttgca attcatcttc 1140
caattgtgta ctatcacctt gaccgctgaa gtcatgtcct acattcactc tatgaactcc 1200
tctatcttgg aaaactggaa cttcgggtgt ccaccaccac caaccacctc cttgggttgac 1260
acttacagat tcgtccaatc tgtcgtgtc acttgtcaaa aggacaccac tccaccagaa 1320
aagcaagacc catacyacaa gttgaagttc tggactgttg acttgaagga aaagtctctc 1380
tccgacttgg accaatcccc attgggtaga aagtctcttg ttcaagctgg tttgagacgt 1440
agaccaacta tcggtccacg taagagacca gctgcttcca cttccactgc ttctagacca 1500
gctaagcgtg tcagaatcag atccaagaag taa 1533

```

<210> 2

<211> 510

<212> PRT

<213> Human Papillomavirus Type 45

<400> 2

```

Met Ala Leu Trp Arg Pro Ser Asp Ser Thr Val Tyr Leu Pro Pro Pro
  1              5              10              15

```

Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Ser Arg Thr Ser  
 20 25 30  
 Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro  
 35 40 45  
 Tyr Phe Arg Val Val Pro Ser Gly Ala Gly Asn Lys Gln Ala Val Pro  
 50 55 60  
 Lys Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Ala Leu Pro Asp  
 65 70 75 80  
 Pro Asn Lys Phe Gly Leu Pro Asp Ser Thr Ile Tyr Asn Pro Glu Thr  
 85 90 95  
 Gln Arg Leu Val Trp Ala Cys Val Gly Met Glu Ile Gly Arg Gly Gln  
 100 105 110  
 Pro Leu Gly Ile Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp  
 115 120 125  
 Asp Thr Glu Ser Ala His Ala Thr Ala Val Ile Thr Gln Asp Val  
 130 135 140  
 Arg Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu  
 145 150 155 160  
 Gly Cys Val Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Leu Cys  
 165 170 175  
 Lys Pro Ala Gln Leu Gln Pro Gly Asp Cys Pro Pro Leu Glu Leu Lys  
 180 185 190  
 Asn Thr Ile Ile Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala  
 195 200 205  
 Met Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp  
 210 215 220  
 Ile Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala  
 225 230 235 240  
 Asp Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu  
 245 250 255  
 Phe Ala Arg His Phe Trp Asn Arg Ala Gly Val Met Gly Asp Thr Val  
 260 265 270  
 Pro Thr Asp Leu Tyr Ile Lys Gly Thr Ser Ala Asn Met Arg Glu Thr  
 275 280 285  
 Pro Gly Ser Cys Val Tyr Ser Pro Ser Pro Ser Gly Ser Ile Thr Thr  
 290 295 300  
 Ser Asp Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln  
 305 310 315 320  
 Gly His Asn Asn Gly Ile Cys Trp His Asn Gln Leu Phe Val Thr Val  
 325 330 335  
 Val Asp Thr Thr Arg Ser Thr Asn Leu Thr Leu Cys Ala Ser Thr Gln  
 340 345 350  
 Asn Pro Val Pro Asn Thr Tyr Asp Pro Thr Lys Phe Lys His Tyr Ser  
 355 360 365  
 Arg His Val Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr  
 370 375 380  
 Ile Thr Leu Thr Ala Glu Val Met Ser Tyr Ile His Ser Met Asn Ser  
 385 390 395 400  
 Ser Ile Leu Glu Asn Trp Asn Phe Gly Val Pro Pro Pro Pro Thr Thr  
 405 410 415  
 Ser Leu Val Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Val Thr Cys  
 420 425 430  
 Gln Lys Asp Thr Thr Pro Pro Glu Lys Gln Asp Pro Tyr Asp Lys Leu  
 435 440 445  
 Lys Phe Trp Thr Val Asp Leu Lys Glu Lys Phe Ser Ser Asp Leu Asp  
 450 455 460  
 Gln Tyr Pro Leu Gly Arg Lys Phe Leu Val Gln Ala Gly Leu Arg Arg  
 465 470 475 480  
 Arg Pro Thr Ile Gly Pro Arg Lys Arg Pro Ala Ala Ser Thr Ser Thr  
 485 490 495  
 Ala Ser Arg Pro Ala Lys Arg Val Arg Ile Arg Ser Lys Lys  
 500 505 510

<210> 3  
 <211> 1533  
 <212> DNA  
 <213> Human Papillomavirus Type 45

<400> 3  
 atggcctttgt ggcggcctag tgacagtacg gtatatcttc caccaccttc tgtggccaga 60  
 gttgtcaaca ctgatgatta tgtgtctcgc acaagcatat ttaccatgc aggcagttcc 120  
 cgattattaa ctgtaggcaa tccatatttt aggggtgtac ctagtggtgc aggtataaaa 180  
 caggctgttc ctaaggatc cgcatatcag tatagggtgt ttagagtagc tttgcccgat 240  
 cctaataaat ttggattacc tgattctact atataatac ctgaaacaca acgtttgggt 300  
 tgggcatgtg taggtatgga aattgggtcgt gggcagcctt taggtattgg cctaagtggc 360  
 catccatttt ataataaatt ggatgataca gaaagtgtc atgcagctac agctgttatt 420  
 acgcaggatg ttagggataa tgtgtcagtt gattataagc aaacacagct gtgtatttta 480  
 ggttgtgtac ctgctattgg tgagcactgg gccaaaggga cactttgtaa acctgcacaa 540  
 ttgcaacctg gtgactgtcc tcctttggaa cttaaaaaa ccattattga ggatgggtgat 600  
 atgggtggata caggttatgg ggcaatggat tttagtacat tgcaggatac aaagtgcgag 660  
 gttccattag acatttgtca atccatctgt aaatatccag attatttgca aatgtctgct 720  
 gatccctatg gggattctat gtttttttgc ctacgccgtg aacaactgtt tgcaagacat 780  
 ttttggaata gggcagggtg tatgggtgac acagtaccta cagacctata tattaaggc 840  
 actagcgcata atatgcgtga aacccttggc agtgtgtgtg attccccctt tccagtggtg 900  
 tctattacta cttctgattc tcaattattt aataagccat attgggttaca taaggcccag 960  
 ggccataaca atggtatttg ttggcataat cagttgtttg ttactgtagt ggacactacc 1020  
 cgcagtacta atttaacatt atgtgcctct acacaaaatc ctgtgccaaa tacatatgat 1080  
 cctactaagt ttaagcacta tagtagacat gtggagggaat atgatttaca gtttattttt 1140  
 cagttgtgca ctattacttt aactgcagag gttatgtcat atatccatag tatgaatagt 1200  
 agtatattgg aaaattggaa ttttgggtga cctccaccac ctactacaag tttagtggtg 1260  
 acatatcgtt ttgtgcaatc agttgtgtgt acctgtcaaa aggatactac acctccagaa 1320  
 aagcaggatc catatgataa attaaagttt tggactgttg acctaaagga aaaattttcc 1380  
 tccgatttgg atcaatatcc ccttgggtcga aagttttttag ttcagggtgg gttacgtcgt 1440  
 aggcctacca taggacctcg taagcgtcct gctgcttcca cgtctactgc atctaggcct 1500  
 gccaaacgtg tacgtatacg tagtaaaaaa taa 1533

<210> 4  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Primer

<400> 4  
 ccaccaccac ctatataggt attc 24

<210> 5  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Primer

<400> 5  
 caaacatata tatatgtgct aaca 24

<210> 6  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Primer

<400> 6  
ctcagatctc acaaaacaaa atggccttgt ggcggcctag tgac

44

<210> 7  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR Primer

<400> 7  
gacagatctt attttttact acgtatacgt acacg

35

<210> 8  
<211> 1533  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> HPV45 L1R - Antisense

<400> 8  
taccgaaaca cctctggtag actgagatga cagatgaacg gtggtggtag acagcgatct 60  
cagcagttgt gactgctgat gcagaggtct tggaggtaga agatgggtgc accaagaagg 120  
tctaacaact gacagccatt gggatatgaag tctcagcagg gtaggccacg accattgttc 180  
gttcgacaag gtttccagag acgaatgggt atgtctcaga agtctcagcg aaacgggtctg 240  
ggtttgttca agccaaacgg tctgagatga tagatgttgg gtctttgagt ttctaaccag 300  
acccgtacgc agccatacct ttagccatct ccagttggta acccatagcc aaacagacca 360  
gtgggtaaga tgttgttcaa cctgctgttg cttaggcgag tgcgacgatg acgacagtag 420  
tgagttctgc agtctctgtt gcagagacag ctgatgttcg tttgggttaa cacatagaac 480  
ccaacacagg gtcgatagcc acttgtgacc cgattcccat ggaacacatt cggtcgagtt 540  
aacgttggtc cactgacagg tggtaacctt aacttcttgt gatagtagct tctgccactg 600  
taccaactgt gaccaatgcc acgatacctg aagaggtggg acgtcctgtg attcacactt 660  
caaggtaacc tgtagacagt tagatagaca ttcattgggtc tgatgaacgt ttacaggcga 720  
ctgggtatgc cactgagata caagaagaca aactcttctc ttgttaacaa gcgatctgtg 780  
aagaccttgt ctgaccaca gtacccactg tgacaagggt gactgaacat gtagttccca 840  
tgagagcagat tgtactctct ttgaggtcca aggacacaga tgagaggtag aggtagacca 900  
agatagtgat gaaggctgag agttaacaag ttgttcggta tgaccaacgt gttccgagtt 960  
ccagtgttgt tgccatagac aaccgtgttg gtaacaagc agtggcagca actgtgatgg 1020  
tctagatgat tgaactggaa cacacgaaga tgagttttgg gtcaagggtt gtgaatgctg 1080  
ggttgggttca agttcgtgat gaggtctgtg cagctcctta tgctgaacgt taagtagaag 1140  
gttaacacat gatagtggaa ctggcgactt cagtacagga tgtaagttag atacttgagg 1200  
agatagaacc ttttgacctt gaagccacaa ggtggtgggt gttggtggag gaaccaactg 1260  
tgaatgtcta agcaggttag acagcgacag tgaacagttt tcctgtgggt aggtggtctt 1320  
ttcgttctgg gtatgctgtt caacttcaag acctgacaac tgaacttcct tttcaagaga 1380  
aggctgaacc tggttatggg taacctatct ttcaagaacc aagttcgacc aaactctgca 1440  
tctggttgat agccaggtgc attctctggt cgacgaaggt gaaggtgacg aagatctggt 1500  
cgattcgcac agtcttagtc taggttcttc att 1533

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7    A61K39/12    C12N15/37    C12N15/81    C07K14/025		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7    A61K    C12N    C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, MEDLINE, EMBL		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TOBERY T W ET AL: "Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 13-14, 28 March 2003 (2003-03-28), pages 1539-1547, XP004412501 ISSN: 0264-410X page 1540 - page 1546	1-25
A	WO 01/14416 A (CHEN LING ; MERCK & CO INC (US); SCHULTZ LOREN D (US); WANG XIN MIN (U) 1 March 2001 (2001-03-01) the whole document <div style="text-align: center; margin-top: 10px;">----- -/--</div>	1-25
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
* Special categories of cited documents:		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&amp;* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
17 December 2004	03/01/2005	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Schulz, R	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ZHOU JIAN ET AL: "Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability"</p> <p>JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 6, June 1999 (1999-06), pages 4972-4982, XP002164427 ISSN: 0022-538X page 4972 - page 4981; table 1</p>	1-25
A	<p>WO 01/41799 A (CELIS ESTEBAN ; GREY HOWARD M (US); SIDNEY JOHN (US); CHESNUT ROBERT ( ) 14 June 2001 (2001-06-14) page 26, line 10 - line 19</p>	1-3
A	<p>DATABASE EMBL GENBANK; L1 protein acc. no. Q9Y4Y5 1 November 1999 (1999-11-01), FAVRE, M. G.: "HPV45 L1" XP002310641 abstract</p>	1-3
A	<p>LIU W J ET AL: "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy"</p> <p>VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 5-6, 12 December 2001 (2001-12-12), pages 862-869, XP004312531 ISSN: 0264-410X the whole document</p>	1-25
A	<p>COOK JAMES C ET AL: "Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae"</p> <p>PROTEIN EXPRESSION AND PURIFICATION, vol. 17, no. 3, December 1999 (1999-12), pages 477-484, XP000441598 ISSN: 1046-5928 page 480 - page 484</p>	1-25
	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NEEPER M P ET AL: "Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae"</p> <p>GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 180, no. 1-2, 21 November 1996 (1996-11-21), pages 1-6, XP004071889</p> <p>ISSN: 0378-1119</p> <p>the whole document</p>	1-25
A	<p>WO 96/15247 A (HOFMANN KATHRYN J ; GEORGE HUGH A (US); JOYCE JOSEPH G (US); LEHMAN ER) 23 May 1996 (1996-05-23)</p> <p>page 2 - page 9; examples 1-38</p>	1-25

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0114416	A	01-03-2001	AU 772611 B2	06-05-2004
			AU 7063900 A	19-03-2001
			CA 2381991 A1	01-03-2001
			EP 1212358 A2	12-06-2002
			JP 2003511010 T	25-03-2003
			WO 0114416 A2	01-03-2001
WO 0141799	A	14-06-2001	AU 2258201 A	18-06-2001
			CA 2393960 A1	14-06-2001
			EP 1246644 A1	09-10-2002
			JP 2004512814 T	30-04-2004
			WO 0141799 A1	14-06-2001
WO 9615247	A	23-05-1996	AT 245192 T	15-08-2003
			AU 708737 B2	12-08-1999
			AU 4365896 A	06-06-1996
			BR 9510520 A	14-07-1998
			CA 2204266 A1	23-05-1996
			CN 1173203 A	11-02-1998
			CZ 9701452 A3	15-10-1997
			DE 69531308 D1	21-08-2003
			DE 69531308 T2	15-04-2004
			DK 789767 T3	20-10-2003
			EP 0789767 A1	20-08-1997
			ES 2201129 T3	16-03-2004
			FI 972030 A	13-05-1997
			HR 950557 A1	31-08-1997
			HU 77559 A2	29-06-1998
			JP 11500002 T	06-01-1999
			NZ 298224 A	28-05-1999
			PT 789767 T	28-11-2003
			RU 2161651 C2	10-01-2001
			SK 59497 A3	04-03-1998
			WO 9615247 A1	23-05-1996



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**